Shares of Histogenics Corp. (NASDAQ:HSGX) were up 3.5% during trading on Monday . The company traded as high as $2.14 and last traded at $2.07, with a volume of 74,228 shares. The stock had previously closed at $2.00.

A number of analysts recently commented on HSGX shares. Canaccord Genuity reissued a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. BTIG Research reaffirmed a “hold” rating on shares of Histogenics Corp. in a report on Sunday, May 15th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $12.13.

The firm’s market cap is $27.20 million. The stock’s 50 day moving average is $1.87 and its 200 day moving average is $2.21.

Histogenics Corp. (NASDAQ:HSGX) last released its earnings results on Thursday, May 12th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.01. During the same quarter in the previous year, the business earned ($0.60) EPS. On average, analysts expect that Histogenics Corp. will post ($2.15) EPS for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.